This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Events & Webinars

Navigating mCRC: Empowering Nurses for Colorectal Cancer Care

Stivarga-BG

In the first Empowering Nurses Webinar series, Dr Rille Pihlak (Barts Health NHS Trust), Ms Emma Ainsworth (Newcastle Hospitals NHS Foundation Trust) and Ms Sarah Selemani (King’s College Hospital NHS Foundation Trust) cover three important topics in mCRC management to encourage confidence in nurses when treating their patients. Watch the series now to gain insight from the experts.

Dr Pihlak provides a comprehensive summary of the Stivarga® (regorafenib) efficacy and tolerability. Ms Ainsworth then discusses the comparison of oral versus intravenous chemotherapies through a nurse’s perspective and the series concludes with Ms Selemani and her view on adverse event management.

Identification of third-line mCRC patients and an overview of the treatment of this patient group with Stivarga

Stivarga Prescribing Information

An overview of oral compared to IV therapy, and advocating for mCRC patients as part of a multidisciplinary team (MDT)

Stivarga Prescribing Information

A discussion on the practical management of adverse events experienced by patients on Stivarga

Stivarga Prescribing Information

Speakers
    • Dr Rille Pihlak
      Dr Rille Pihlak

    Rille is currently a consultant medical oncologist at St Bart's Hospital in London. She is originally from Estonia and finished her undergraduate medical degree and postgraduate training in Oncology there in 2016. She was then awarded The Collins/Pancreatic Cancer UK Clinical Research PhD Fellowship at The University of Manchester/The Christie NHS Foundation Trust. She successfully defended her PhD on pancreatic cancer in 2021 and then joined The Royal Marsden GI unit for a Senior Research Fellowship. In 2022 she was appointed as a consultant medical oncologist in GI cancers at St Bart's Hospital.

    Outside of her current clinical role, she has various other international roles like being a member of the European Society for Medical Oncology (ESMO) Young Oncologist Committee and co-chair of the Postgraduate Medical Education Committee in The International Association for Medical Education (AMEE).

    • Ms Emma Ainsworth
      Ms Emma Ainsworth

    Emma is currently a Trainee Advanced Clinical practitioner in Oncology GI. She works in the Northern Centre for Cancer Care in Newcastle, having previously held the Upper GI/ HPB Clinical Nurse Specialist post for 14 years.

    Within the Oncology service, Emma has many years of experience in setting up and running completely nurse led clinics, reviewing side effects and prescribing chemotherapy.

    • Ms Sarah Selemani
      Ms Sarah Selemani

    Sarah is a Lead Nurse for Hepatocellular Carcinoma at King’s College Hospital in London. Working within a tertiary referral centre for HCC, her education includes MSc in Advanced Clinical Practice and non-medical prescribing including SACT prescribing. The HCC service includes nurse led services including non-medical follow up for patients on SACT, pre-assessment and discharge review alongside providing support to patients throughout their HCC journey.

    Sarah is the nurse representative on the HCC UK panel and has been part of national guidelines committee for HCC and conference planning. A speaker at national and international conferences; she has a passion for the HCC patient experience and improving access and supportive care.

UKOF 2023 Symposium
Stivarga® (regorafenib)
PP-STI-GB-0274, February 2024
The treatment landscape in mCRC
Stivarga® (regorafenib)
PP-STI-GB-0202, February 2024
Expert opinion
Stivarga® (regorafenib)
PP-STI-GB-0200, February 2024

PP-STI-GB-0396 | July 2024